The clinical consequence of HER2 protein overexpression and/or HER2/neu amplification is a biologically aggressive phenotype; 15–20% of primary breast cancers are HER2-positive [1, 3, 30]. This evidence concerns the gene ERBB2 and breast carcinoma.